Maverick Capital Ltd. Has $231.17 Million Stake in Natera, Inc. $NTRA

Key Points

• Maverick Capital Ltd. increased its stake in Natera, Inc. by 19.7%, acquiring an additional 268,715 shares, making Natera its 5th largest holding at 4.1% of their investment portfolio.
• Several institutional investors also significantly increased their holdings in Natera during the first quarter, including Focus Partners Advisor Solutions LLC, which boosted its stake by 144.2%.
• Natera's recent earnings report indicated a 32.2% increase in quarterly revenue year-over-year, but the company reported a loss of ($0.74) earnings per share, missing analysts' estimates.

Maverick Capital Ltd. lifted its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 19.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,634,769 shares of the medical research company's stock after purchasing an additional 268,715 shares during the period. Natera accounts for approximately 4.1% of Maverick Capital Ltd.'s investment portfolio, making the stock its 5th biggest holding. Maverick Capital Ltd. owned approximately 1.21% of Natera worth $231,173,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock worth $1,752,611,000 after purchasing an additional 77,357 shares during the period. Price T Rowe Associates Inc. MD grew its position in Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock worth $1,490,144,000 after buying an additional 3,795,315 shares in the last quarter. JPMorgan Chase & Co. grew its position in Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after buying an additional 660,538 shares in the last quarter. Invesco Ltd. grew its position in Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock worth $287,908,000 after buying an additional 245,719 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its position in Natera by 5.6% during the first quarter. Lord Abbett & CO. LLC now owns 1,521,300 shares of the medical research company's stock worth $215,127,000 after buying an additional 80,865 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In related news, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the transaction, the director directly owned 8,118 shares of the company's stock, valued at $1,358,628.48. This trade represents a 34.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 6,092 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $139.81, for a total value of $851,722.52. Following the transaction, the chief executive officer directly owned 169,400 shares of the company's stock, valued at approximately $23,683,814. This represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 52,344 shares of company stock worth $7,771,750 over the last 90 days. Company insiders own 5.63% of the company's stock.

Natera Trading Up 0.9%

NASDAQ:NTRA traded up $1.46 during trading hours on Friday, hitting $168.02. 776,006 shares of the company were exchanged, compared to its average volume of 1,483,312. The stock has a market capitalization of $23.06 billion, a price-to-earnings ratio of -87.97 and a beta of 1.68. Natera, Inc. has a one year low of $110.57 and a one year high of $183.00. The company has a fifty day simple moving average of $154.35 and a 200 day simple moving average of $153.92.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NTRA shares. Royal Bank Of Canada set a $268.00 price target on Natera and gave the stock an "outperform" rating in a research report on Tuesday. Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Cowen reaffirmed a "buy" rating on shares of Natera in a report on Friday, August 8th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a report on Monday, July 28th. Finally, Stephens reaffirmed an "overweight" rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company. According to data from MarketBeat.com, Natera has an average rating of "Buy" and a consensus price target of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.